Tella Biotech

Tella was a Japanese biotechnology company specializing in the development and commercialization of dendritic cell-based cancer immunotherapies. The company's core business revolved around its proprietary dendritic cell vaccine technology, which was provided to medical institutions to treat various cancers, most notably pancreatic cancer and leukemia. Tella operated a network of cell processing centers and collaborated with academic institutions to advance its pipeline of personalized cancer vaccines. Despite achieving Phase 3 clinical milestones for its lead programs, the company faced significant financial difficulties and legal challenges, leading to its bankruptcy and delisting in 2022.